Shares of Novo Nordisk A/S (NYSE:NVO) have earned a consensus rating of “Hold” from the seventeen analysts that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $159.65.
Several equities research analysts have recently weighed in on NVO shares. ValuEngine cut Novo Nordisk A/S from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 5th. UBS Group reissued a “buy” rating and issued a $355.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, June 19th. Citigroup raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a research report on Monday, July 15th. Finally, Bank of America increased their price objective on Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th.
NVO stock traded up $0.45 during midday trading on Thursday, hitting $52.48. 489,107 shares of the company traded hands, compared to its average volume of 1,408,905. Novo Nordisk A/S has a twelve month low of $41.59 and a twelve month high of $53.55. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.06. The business has a 50 day simple moving average of $51.67 and a 200-day simple moving average of $50.12. The stock has a market capitalization of $121.31 billion, a price-to-earnings ratio of 20.83, a price-to-earnings-growth ratio of 2.14 and a beta of 0.58.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Friday, August 9th. The company reported $0.61 EPS for the quarter, meeting the consensus estimate of $0.61. Novo Nordisk A/S had a return on equity of 75.16% and a net margin of 32.16%. The company had revenue of $4.52 billion for the quarter, compared to the consensus estimate of $4.41 billion. Equities research analysts forecast that Novo Nordisk A/S will post 2.43 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Ferguson Wellman Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 3.8% in the third quarter. Ferguson Wellman Capital Management Inc. now owns 182,130 shares of the company’s stock valued at $9,416,000 after acquiring an additional 6,664 shares during the period. Smithbridge Asset Management Inc. DE lifted its position in Novo Nordisk A/S by 1.0% in the third quarter. Smithbridge Asset Management Inc. DE now owns 76,719 shares of the company’s stock worth $3,966,000 after purchasing an additional 795 shares during the period. Cim LLC lifted its position in Novo Nordisk A/S by 1.8% in the third quarter. Cim LLC now owns 199,565 shares of the company’s stock worth $10,317,000 after purchasing an additional 3,476 shares during the period. Atwater Malick LLC lifted its position in Novo Nordisk A/S by 5.2% in the third quarter. Atwater Malick LLC now owns 76,422 shares of the company’s stock worth $3,951,000 after purchasing an additional 3,754 shares during the period. Finally, OmniStar Financial Group Inc. lifted its position in Novo Nordisk A/S by 0.3% in the third quarter. OmniStar Financial Group Inc. now owns 65,282 shares of the company’s stock worth $3,375,000 after purchasing an additional 204 shares during the period. 7.34% of the stock is owned by institutional investors.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
See Also: Why do corrections happen?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.